Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Curasight A/S announces outcome of T03 warrant exercise | 2 | Cision News | ||
CURASIGHT Aktie jetzt für 0€ handeln | |||||
18.06. | Curasight A/S submits Clinical Trial Application for Phase 1 trial with uTREAT in brain cancer patients | 1 | Cision News | ||
13.06. | Spotlight Stock Market: Market Notice 110/25 - Last day of trading in Curasight A/S's subscription option CURAS TO 3 | 1 | Cision News | ||
03.06. | CURASIGHT: The exercise period commences for warrants of series TO3 on 4 June 2025 | 1 | Cision News | ||
02.06. | Curasight carries out a directed issue of shares to guarantors in connection with the completed rights issue | 1 | Cision News | ||
28.05. | CURASIGHT: Completed registration of rights issue | 1 | Cision News | ||
28.05. | Resolutions of the Annual General Meeting 2025 of Curasight A/S | 1 | Cision News | ||
21.05. | Curasight announces outcome in rights issue | 1 | Cision News | ||
15.05. | Subscription of new shares in the Right Issue 2025 exercised by Curasight management | 1 | Cision News | ||
13.05. | CURASIGHT: Notice of Annual General Meeting 2025 | 1 | Cision News | ||
13.05. | Last day of the subscription period in Curasight's rights issue of shares | 2 | Cision News | ||
07.05. | Curasight A/S selects CRO to run Phase 1 trial with uTREAT[®] in brain cancer | 2 | Cision News | ||
06.05. | Curasight's rights issue subscription period has commenced | 2 | Cision News | ||
02.05. | THE SUBSCRIPTION PERIOD IN CURASIGHT'S RIGHTS ISSUE OF SHARES BEGINS TODAY | 2 | Cision News | ||
30.04. | Curasight to present at HC Andersen Capital | 2 | Cision News | ||
29.04. | Curasight A/S publishes disclosure document regarding rights issue | 2 | Cision News | ||
28.04. | Spotlight Stock Market: Market Notice 73/25 - Information regarding the rights issue from Curasight A/S | 2 | Cision News | ||
25.04. | CURASIGHT: Annual Report for the fiscal year 2024 | 1 | Cision News | ||
25.04. | CURASIGHT: Interim report Q1 2025 | 1 | Cision News | ||
24.04. | CURASIGHT A/S ANNOUNCES FINAL TERMS OF RIGHTS ISSUE | 1 | Cision News |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Evotec-Aktie: Kurs legt zu (6,734 €) | Am deutschen Aktienmarkt notiert die Evotec-Aktie derzeit etwas fester. Zuletzt zahlten Investoren für das Wertpapier 6,73 Euro. Der Anteilsschein von Evotec verzeichnet gegenwärtig einen Preisanstieg... ► Artikel lesen | |
ADMA BIOLOGICS | 18,310 | -0,38 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
KYMERA THERAPEUTICS | 44,800 | -2,01 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,210 | -3,70 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
BIONTECH | 91,45 | +0,88 % | BioNTech-Aktie: Merkwürdiges Kursverhalten | © Foto: SymbolbildDer steinige Weg vom Corona-Helden zum Krebs-Jäger. So hätte auch die Überschrift lauten können, denn die Mainzer sorgen derzeit für Aufsehen mit Übernahmen und Kooperationen. Einmal... ► Artikel lesen | |
ONCO-INNOVATIONS | 1,380 | +10,40 % | EQS-Media: Onco-Innovations Ltd.: Erhebliche Aufwärtsperspektive für frühe Investoren? Neue Studie unterstützt die Anwendbarkeit der Ergebnisse klinischer Lungenkrebsstudien | EQS-Media / 21.06.2025 / 15:37 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass die Mitbegründer seiner hundertprozentigen... ► Artikel lesen | |
VOR BIOPHARMA | 1,190 | +33,71 % | Pre-market Movers: Vor Biopharma, Worthington Steel, Surf Air Mobility, Nano Labs, Protagenic Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the Green Vor Biopharma Inc. (VOR) is up over 109% at $1.16.
Worthington... ► Artikel lesen | |
ARS PHARMACEUTICALS | 18,700 | +3,37 % | ARS Pharmaceuticals, Inc. - 8-K, Current Report | ||
ARCUTIS BIOTHERAPEUTICS | 14,005 | -2,68 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
ARCELLX | 65,88 | +1,68 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 21,070 | -1,13 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target | ||
MODERNA | 23,305 | +0,17 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
NUVALENT | 81,16 | +2,42 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen |